Heart failure & cardiomyopathiesSecondary analysis
Finerenone and quality of life in heart failure: component-level analyses and clinical relevance of the Kansas City cardiomyopathy questionnaire
- Secondary analysis of the FINEARTS-HF randomised trial
- prespecified analysis
- double-blind
- placebo-controlled
- exploratory
Authors' conclusion
In FINEARTS-HF, finerenone was associated with modest improvements in health status-most notably lower limb oedema and fatigue-in patients with HFmrEF/HFpEF.
Study context
- Population
- Patients with HF with mildly reduced or preserved EF (HFmrEF/HFpEF) who completed the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline and 12 monthsof 6001 in FINEARTS-HF
- Participants
- 5,006 patients
- Comparison
- Finerenone vs placebo
- Primary endpoint
- Mean change from baseline in each of the 23 KCCQ components (0 worst to 100 best)
- Follow-up
- 12 months
Primary result
As reported in the abstract
KCCQ component change, finerenone vs placebo
Difference
- lower limb oedema frequency
- +2.5 (95% CI 0.9–4.1)
- fatigue burden
- +2.2 (95% CI 0.9–3.5)
- fatigue frequency
- +2.1 (95% CI 0.7–3.6)
- lower limb oedema burden
- +1.8 (95% CI 0.6–2.9)
Further findings
| Outcome | shift in age-KCCQ-OSS relationship (years) (95% CI) |
|---|---|
| KCCQ-OSS vs expected age-related decline · 12 months | 4.7 (0.4–9.1) |
KCCQ-overall summary score (KCCQ-OSS) vs expected age-related decline · 12 months
- KCCQ-OSS at 12 months inversely related to age
Original publication
Finerenone and quality of life in heart failure: component-level analyses and clinical relevance of the Kansas City cardiomyopathy questionnaire. Eur J Heart Fail. Published 12 March 2026. doi:10.1093/ejhf/xuag062
Summarised from the published abstract; every number is checked against it